Ropinirole
- Generic Name
- Ropinirole
- Brand Names
- Requip
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2O
- CAS Number
- 91374-21-9
- Unique Ingredient Identifier
- 030PYR8953
- Background
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary ...
- Indication
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .
- Associated Conditions
- Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
DIalysis Symptom COntrol-Restless Legs Syndrome Trial
- Conditions
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 52
- Registration Number
- NCT03806530
- Locations
- 🇨🇦
The Ottawa Hospital, Ottawa, Ontario, Canada
🇨🇦St. Joseph's Hamilton Healthcare, Hamilton, Ontario, Canada
🇨🇦Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD
- Conditions
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 3
- Registration Number
- NCT03708237
- Locations
- 🇨🇦
Edmonton General Continuing Care Centre, Edmonton, Canada
🇨🇦Royal Alexandra Hospital, Edmonton, Canada
🇨🇦Grey Nuns Community Hospital, Edmonton, Canada
Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT03176966
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
- First Posted Date
- 2017-01-31
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 16
- Registration Number
- NCT03038308
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients
- Conditions
- Interventions
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT01628926
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 48
- Registration Number
- NCT01627834
- Locations
- 🇮🇳
GVK Biosciences Pvt. Ltd, Ameerpet, Hyderabad, India
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition
- First Posted Date
- 2012-06-26
- Last Posted Date
- 2012-09-28
- Lead Sponsor
- Dr. Reddy's Laboratories Limited
- Target Recruit Count
- 48
- Registration Number
- NCT01627847
- Locations
- 🇮🇳
GVK Biosciences Pvt. Ltd, Ameerpet, Hyderabad, Andhra Pradesh, India
Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT01435915
- Locations
- 🇨🇳
GSK Investigational Site, Beijing, China
REQUIP RLS Post Marketing Surveillance
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 755
- Registration Number
- NCT01327339
Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type
- Conditions
- First Posted Date
- 2008-03-19
- Last Posted Date
- 2008-03-19
- Lead Sponsor
- University of Turku
- Target Recruit Count
- 16
- Registration Number
- NCT00639119
- Locations
- 🇫🇮
Turku university central hospital, Department of neurology, Turku, Finland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.